Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 1;29(4):835-856.
doi: 10.1093/annonc/mdy038.

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

D Arnold  1 , G W Prager  2 , A Quintela  3 , A Stein  4 , S Moreno Vera  5 , N Mounedji  5 , J Taieb  6
Affiliations

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

D Arnold et al. Ann Oncol. .

Abstract

Background: The optimal chemotherapeutic regimen for use beyond the second line for patients with metastatic colorectal cancer (mCRC) remains unclear.

Materials and methods: We systematically searched the Cochrane Database of Systematic Reviews, EMBASE and Medline for records published between January 2002 and May 2017, and cancer congress databases for records published between January 2014 and June 2017. Eligible studies evaluated the efficacy, safety and patient-reported outcomes of monotherapies or combination therapies at any dose and number of treatment cycles for use beyond the second line in patients with mCRC. Studies were assessed for design and quality, and a qualitative data synthesis was conducted to understand the impact of treatment on overall survival and other relevant cancer-related outcomes.

Results: The search yielded 938 references of which 68 were included for qualitative synthesis. There was limited evidence to support rechallenge with chemotherapy, targeted therapy or both. Compared with placebo, an overall survival benefit for trifluridine/tipiracil (also known as TAS-102) or regorafenib has been shown for patients previously treated with conventional chemotherapy and targeted therapy. There was no evidence to suggest a difference in efficacy between these treatments. Patient choice and quality of life at this stage of treatment should also be considered when choosing an appropriate therapy.

Conclusions: These findings support the introduction of an approved agent such as trifluridine/tipiracil or regorafenib beyond the second line before any rechallenge in patients with mCRC who have failed second-line treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study selection process.
See this image and copyright information in PMC

Comment in

References

    1. Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27(8): 1386–1422. - PubMed
    1. McQuade RM, Stojanovska V, Bornstein JC, Nurgali K.. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem 2017; 24: 1537–1557. - PubMed
    1. Maindrault-Goebel F, Tournigand C, André T. et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15(8): 1210–1214. - PubMed
    1. Tonini G, Imperatori M, Vincenzi B. et al. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res 2013; 32(1): 92. - PMC - PubMed
    1. McLean J, Rho YS, Kuruba G. et al. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. Clin Colorectal Cancer 2016; 15(2): 135–140. - PubMed

Publication types

MeSH terms